G
Giulia Pasello
Researcher at University of Padua
Publications - 158
Citations - 2672
Giulia Pasello is an academic researcher from University of Padua. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 113 publications receiving 1597 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Alberto Pavan,Lorenzo Calvetti,Alessandro Dal Maso,Ilaria Attili,Paola Del Bianco,Giulia Pasello,Valentina Guarneri,Giuseppe Aprile,Pierfranco Conte,Laura Bonanno +9 more
TL;DR: NLR and PLR may predict the appearance of irAEs in non-oncogene-addicted aNSCLC, although this conclusion warrants prospective validation.
Journal ArticleDOI
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Paolo Andrea Zucali,Tommaso De Pas,Giovannella Palmieri,Adolfo Favaretto,Antonio Chella,Marcello Tiseo,Michele Caruso,Matteo Simonelli,Matteo Perrino,Fabio De Vincenzo,Francesca Toffalorio,Vincenzo Damiano,Giulia Pasello,Erika Garbella,M. Ali,Fabio Conforti,Margaret Ottaviano,Angela Cioffi,Sabino De Placido,Laura Giordano,Monica Bertossi,Annarita Destro,Luca Di Tommaso,Armando Santoro +23 more
TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.
Journal ArticleDOI
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Giulia Pasello,Alberto Pavan,Ilaria Attili,Alberto Bortolami,Laura Bonanno,Jessica Menis,Pierfranco Conte,Valentina Guarneri +7 more
TL;DR: The present review focuses on RWE about ICIs in lung cancer treatment, with particular reference to special patient populations, and discusses potential application of real-world data in a potential innovative drug development model.